Network meta-analysis comparing the effectiveness of a prescription digital therapeutic for chronic insomnia to medications and face-to-face cognitive behavioral therapy in adults

CONCLUSIONS: This network meta-analysis demonstrated that a PDT delivering CBT-I had the highest probability of being most effective compared to face-to-face CBT-I, prescription sleep medications, or placebo, as measured by reductions in mean ISI score from baseline and ISI-determined remittance.* Somryst is the registered trademark for a prescription digital therapeutics for insomnia developed by Pear Therapeutics (US), Inc.PMID:35938209 | DOI:10.1080/03007995.2022.2108616
Source: Current Medical Research and Opinion - Category: Research Authors: Source Type: research